GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Net Intangibles Purchase And Sale

CRISPR Therapeutics AG (LTS:0VRQ) Net Intangibles Purchase And Sale : $0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

CRISPR Therapeutics AG's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.0 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Mar. 2024 was $0.0 Mil.

CRISPR Therapeutics AG Net Intangibles Purchase And Sale Historical Data

The historical data trend for CRISPR Therapeutics AG's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Net Intangibles Purchase And Sale Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2.50

CRISPR Therapeutics AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CRISPR Therapeutics AG Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
CYTK NUVL FOLD TRML KRYS BPMC AXSM CORT DNA INSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CRSP:USA CRSP:Mexico
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Website
https://www.crisprtx.com
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines